Amu­nix grabs $73M from Fra­zier, Omega to fu­el shift to T cell en­gagers

A lit­tle over a year ago, Ang­ie You was run­ning com­mer­cial for a mid-sized Cana­di­an biotech when she got an email from an in­vest­ment firm with an off­beat pro­pos­al.

Fra­zier Health Part­ners was giv­ing seed mon­ey to a 15-year-old com­pa­ny called Amu­nix. The biotech had long sup­plied half-life ex­ten­sion tech­nol­o­gy to big-name drug­mak­ers, and now, af­ter the death of one of the founders, Fra­zier was try­ing to turn it around en­tire­ly in­to a biotech that would make its own drugs. The change re­quired not on­ly a shift in tech­nol­o­gy, but al­so a sig­nif­i­cant shift in strat­e­gy. To that point, the com­pa­ny hadn’t tak­en a sin­gle in­vest­ment dol­lar.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.